Evaluating the Impact of the COVID-19 Opioid Agonist Therapy Guidelines

Opioid agonist therapy (OAT), including methadone, buprenorphine/naloxone (i.e., Suboxone), and Kadian, is the most effective treatment for opioid use disorder. During the COVID-19 pandemic, guidelines for OAT were developed with a focus on with a focus on making it easier to reduce contact with others, while still allowing those in need to access to OAT.     
The goal of this study is to explore the experiences of OAT prescribers and clients on OAT during the COVID-19 pandemic (March 17, 2020 and onward). You will be asked to complete one 15-30 minute online survey. You will be eligible to receive your choice of one $15 gift card (either Walmart, PC, Tim Horton’s, or Ultimate Dining Card) as a thank you for your time. It may take up to three weeks to process your compensation.

Individuals are eligible if they

  • Are 18 years or older
  • Live in Ontario
  • Read English or French
  • Are currently being treated for opioid use disorder using any of these medications:
    o Buprenorphine/naloxone (Suboxone, Subutex, Sublocade)
    o Methadone
    o Kadian
  • OR if they prescribe OAT in Ontario

Location of study 

FOR CLIENTS: Online at https://form.simplesurvey.com/f/l/OATclient

FOR PRESCRIBERS: Online at https://form.simplesurvey.com/f/l/OATPrescriber

Recruitment via

  • Self-Referral (by participant) 
  • Internal Referral (by ROMHC staff) 
  • External Referral (by doctors or other mental health specialist outside of ROMHC) 

Principal Investigator

Kim Corace, PhD


Kelly Suschinsky
(613)-722-6521 ext. 7048